Inicio>>Signaling Pathways>> Proteases>> Mitochondrial Metabolism>>MSDC-0602

MSDC-0602 (Synonyms: MSDC-0602)

Catalog No.GC36658

MSDC-0602 (MSDC-0602), una tiazolidinediona (TZD) ahorradora de PPARγ interactÚa con el portador de piruvato mitocondrial (MPC) e inhibe su actividad y tiene el potencial para el estudio de diabetes tipo 2 con la reducciÓn del riesgo de PPARγ efectos

Products are for research use only. Not for human use. We do not sell to patients.

MSDC-0602 Chemical Structure

Cas No.: 1133819-87-0

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
61,00 $
Disponible
5mg
56,00 $
Disponible
10mg
83,00 $
Disponible
50mg
334,00 $
Disponible
100mg
603,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MSDC-0602, a PPARγ-sparing thiazolidinedione (TZD), interacts with the mitochondrial pyruvate carrier (MPC) and inhibits its activity and are effective for treatment of type 2 diabetes with reducing risk of PPARγ-mediated side effects[1][2].

[1]. Chen Z, et al. Resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J Biol Chem. 2012 Jul 6;287(28):23537-48. [2]. Vigueira PA, et al. The beneficial metabolic effects of sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism. Exp Physiol. 2017 Aug 1;102(8):985-999.

Reseñas

Review for MSDC-0602

Average Rating: 5 ★★★★★ (Based on Reviews and 20 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MSDC-0602

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.